3 Stocks I'm Not Selling No Matter What the Market Does for the Next 20 Years

The article argues that Berkshire Hathaway, Intuitive Surgical, and Nvidia are long-term hold candidates due to durable business models, strong management, and attractive valuations. Nvidia posted Q1 revenue of $81.6B, up 85% year over year, with data center revenue of $75.2B, up 92%, while Intuitive Surgical reported 17% procedure growth and 23% revenue growth in its first quarter. The piece is broadly bullish on all three names but is primarily opinion/analysis rather than new market-moving information.

Analysis

The common thread here is not “quality” in the abstract; it’s three different forms of economic moat durability. BRK.B is the balance-sheet hedge: in a drawdown, its insurance float, non-cyclical cash generation, and uncorrelated operating mix should make it behave more like a defensive capital allocator than a financial stock. The second-order effect is that if markets correct, Berkshire can become a forced-liquidity buyer of assets at better terms, which should widen its relative advantage versus levered conglomerates and highly financialized mega-caps.

ISRG’s setup is more interesting than the headline growth rate suggests. The key debate is not whether robotics adoption continues, but whether procedure mix expansion and installed-base monetization can offset any slowdown in system placements if hospitals stretch capex budgets. If management keeps converting more procedures into consumables/service revenue, the company’s valuation can de-rate without breaking the equity story; if AI-driven competitive claims remain mostly hype, the stock’s recent weakness may be an entry point rather than a structural warning.

NVDA remains the highest beta way to express the AI capex cycle, but the hidden risk is concentration, not valuation. When hyperscaler spending is this elevated, the stock is effectively a proxy for whether data-center buildouts stay on schedule and whether supply constraints move from GPUs to networking, power, and rack integration. The longer-term bear case is not a collapse in demand, but margin normalization as customers push back on pricing and alternative accelerators/csps emerge; that would matter over 6-18 months, not next quarter.

Consensus is likely underestimating how differently these names trade in a risk-off tape: BRK.B should attract capital seeking embedded optionality, ISRG can compound if procedure growth remains mid-teens, and NVDA may remain the best momentum expression but with the sharpest downside if AI spending pauses. The article is implicitly long-duration, but the best risk/reward may be in buying weakness selectively rather than chasing strength, especially with all three still exposed to multiple compression if rates stay sticky.

Key Decisions for Investors

• Overweight BRK.B on any 5-10% market pullback; target a 12-18 month hold as a defensive compounder with lower beta and crisis alpha characteristics.
• Initiate a starter long ISRG position on weakness if it trades below its recent forward multiple band; thesis is 12-24 months of mid-teens procedure growth plus recurring revenue insulation, with downside if hospital capital budgets tighten.
• Maintain core NVDA exposure but trim into sharp rallies; use a 6-12 month horizon and consider call spreads rather than outright stock to limit multiple-compression risk if hyperscaler capex slows.
• Pair trade idea: long ISRG / short a basket of lower-quality medtech names if you expect robotics adoption to consolidate around the dominant platform over the next 6-18 months.
• For a more tactical hedge, buy NVDA downside protection into earnings or major capex updates; the risk/reward improves if implied volatility is still below realized move potential.